We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
(-16%)
Cap. Flow
-$92.5M
Cap. Flow
% of AUM
-4.18%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$14.4M |
| 2 |
Centene
CNC
|
+$8.41M |
| 3 |
Sanofi
SNY
|
+$6.73M |
| 4 |
Eli Lilly
LLY
|
+$6.66M |
| 5 |
IQVIA
IQV
|
+$6.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$15.5M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$12.5M |
| 3 |
Johnson & Johnson
JNJ
|
+$11.1M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$10.3M |
| 5 |
Elevance Health
ELV
|
+$9.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.66% |
| 2 | Real Estate | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$163B
| $141M | 6.38% |
1,888,305
-2,271
| -0.1% | -$157K |
|
2
Amgen
AMGN
$209B
| $122M | 5.5% |
599,871
-17,556
| -3% | -$3.83M |
|
3
Vertex Pharmaceuticals
VRTX
$122B
| $116M | 5.23% |
485,730
-8,059
| -2% | -$1.85M |
|
|
4
Johnson & Johnson
JNJ
$617B
| $110M | 4.97% |
838,769
-78,058
| -9% | -$11.1M |
|
|
5
Biogen
BIIB
$30.7B
| $105M | 4.76% |
332,735
+47,609
| +17% | +$14.4M |
|
|
6
Regeneron Pharmaceuticals
REGN
$77.4B
| $83.4M | 3.77% |
170,878
-30,399
| -15% | -$12.5M |
|
|
7
Merck
MRK
$321B
| $78.7M | 3.56% |
1,071,681
-197,849
| -16% | -$15.5M |
|
8
Illumina
ILMN
$31B
| $72.5M | 3.28% |
272,748
-7,486
| -3% | -$2.09M |
|
9
Pfizer
PFE
$142B
| $59.4M | 2.69% |
1,918,541
-279,416
| -13% | -$9.52M |
|
10
UnitedHealth
UNH
$383B
| $56.6M | 2.56% |
226,827
-22,002
| -9% | -$6.05M |
|
11
Bristol-Myers Squibb
BMY
$132B
| $47.1M | 2.13% |
844,932
+70,070
| +9% | +$4.28M |
|
12
Medtronic
MDT
$110B
| $40.3M | 1.82% |
447,011
-23,801
| -5% | -$2.53M |
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
| $37.1M | 1.68% |
413,326
-22,488
| -5% | -$2.21M |
|
14
Abbott
ABT
$183B
| $36.8M | 1.66% |
466,550
-5,285
| -1% | -$441K |
|
|
15
Eli Lilly
LLY
$1.03T
| $35.9M | 1.62% |
258,669
+48,488
| +23% | +$6.66M |
|
16
Thermo Fisher Scientific
TMO
$214B
| $31.8M | 1.44% |
112,025
-11,383
| -9% | -$3.59M |
|
17
Incyte
INCY
$24.9B
| $31.7M | 1.43% |
432,246
+49,016
| +13% | +$3.7M |
|
18
CVS Health
CVS
$134B
| $29.5M | 1.34% |
497,986
| – | – |
|
|
AGN
19
DELISTED
Allergan plc
AGN
| $28M | 1.26% |
157,981
-1,600
| -1% | -$301K |
|
20
AbbVie
ABBV
$455B
| $26M | 1.17% |
340,916
| – | – |
|
21
Cigna
CI
$76.1B
| $25.3M | 1.14% |
142,655
-47,900
| -25% | -$9.29M |
|
|
SGEN
22
DELISTED
Seagen Inc. Common Stock
SGEN
| $24.8M | 1.12% |
214,530
-62,236
| -22% | -$6.89M |
|
23
BioMarin Pharmaceuticals
BMRN
$11.7B
| $22.9M | 1.03% |
270,613
-5,947
| -2% | -$512K |
|
24
Stryker
SYK
$133B
| $22.6M | 1.02% |
135,795
+22,128
| +19% | +$4.32M |
|
25
Danaher
DHR
$138B
| $22.1M | 1% |
179,749
-6,908
| -4% | -$931K |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.
Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.
- Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
- Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
- Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
- Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
- Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
- Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
- Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.
Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.